# US 2025/0152565 A1 · Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152565 A1
- Document ID: US20250152565A1
- Status: Published application
- Kind: A1
- Application number: 19/020,135
- Filed: 2025-01-14
- Published: 2025-05-15
- Earliest claimed: 2021-02-19
- Assignees: Universitätsspital Basel
- Applicants: UniversitäTsspital Basel
- Inventors: Matthias Emanuel LIECHTI; Friederike Sophie HOLZE
- Web page: https://patentgrep.com/patent/US20250152565A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method of treating generalized anxiety disorder in an individual comprising:
administering 25-400 μg of LSD, or a salt thereof, wherein the administration of 25-400 μg of LSD, or a salt thereof, results in a reduced STAI global score.

### Claim 19 (depends on 18)

The method of claim 18, wherein a second dose of LSD, or a salt thereof, is administered four to five weeks after said administering step.

### Claim 20 (depends on 18)

The method of claim 18, when the subject also has depression or low mood associated or co-present with the anxiety.

### Claim 21 (depends on 18)

The method of claim 18, wherein the administration of LSD, or a salt thereof, results in reduced psychological distress.

### Claim 22 (depends on 18)

The method of claim 18, wherein the administration of LSD, or a salt thereof, results in an increased quality of life in the individual.

### Claim 23 (depends on 18)

The method of claim 18, further including the step of providing psychotherapy to the individual on separate days before and after administration of LSD, or a salt thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the administration of LSD, or a salt thereof, enhances the therapeutic effect of the psychotherapy.

### Claim 25 (depends on 18)

The method of claim 18, wherein the LSD, or a salt thereof, is administered in the presence of a therapist for 12 hours in a quiet room.

### Claim 26 (depends on 25)

The method of claim 25, wherein the individual is lying in a bed or sitting in a chair and listening to music.

### Claim 27 (depends on 19)

The method of claim 19, wherein the second dose of LSD, or a salt thereof, is administered in the presence of a therapist for 12 hours in a quiet room.

### Claim 28 (depends on 27)

The method of claim 27, wherein the individual is lying in a bed or sitting in a chair and listening to music.

### Claim 29 (depends on 18)

The method of claim 18, wherein the individual was tapered off an antidepressant at least two weeks before administration of LSD, or a salt thereof.

### Claim 30 (depends on 18)

The method of claim 18, wherein the STAI global score is reduced by 10-points in about four weeks or greater after administration of LSD, or a salt thereof.

### Claim 31 (depends on 18)

The method of claim 18, wherein the STAI global score is reduced by 10-points in about ten weeks or greater after administration of LSD, or a salt thereof.

### Claim 32 (depends on 18)

The method of claim 18, wherein the STAI global score is reduced by 20-points in about ten weeks or greater after administration of LSD, or a salt thereof.
